Results 211 to 220 of about 291,982 (298)

Second-look ultrasound with positron emission tomography (PET) for evaluating recurrent lesions of medullary thyroid cancer: a case description. [PDF]

Quant Imaging Med Surg
Gao L, Li J, Liu H, Xia Y, Li B, Huo L, Li N, Jiang Y.   +7 more
europepmc   +1 more source

Effect of Interval Between Neoadjuvant Immunochemotherapy and Radical Resection of Non‐Small Cell Lung Cancer: A Multicenter, Retrospective Cohort Study

International Journal of Cancer, EarlyView.
The optimal timing of surgery after neoadjuvant immunochemotherapy (NICT) for locally advanced non‐small cell lung cancer (NSCLC) remains unclear. In this retrospective investigation, the impact of time interval on outcome was assessed among NSCLC patients who completed NICT before undergoing radical resection.
Jiayi Wang, Pingping Song, Yong Ge, Haitang Yang, Shuyuan Li, Ran Ma, Tianyue Ma, Shoujie Feng, Cheng Zhang, Teng Sun, Feng Yao, Jun Yi, Hao Zhang   +12 more
wiley   +1 more source

Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial

International Journal of Cancer, EarlyView.
Surgery plus chemotherapy is a well‐established treatment protocol for resectable, locally advanced non‐small cell lung cancer (NSCLC). Nonetheless, survival gains remain limited, emphasizing the need for more effective treatments. Here, the authors evaluated a novel approach using a neoadjuvant immunotherapy‐chemotherapy regimen consisting of ...
Benedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn, Raffaella Griffo, Laura V. Klotz, Michael Allgäuer, Albrecht Stenzinger, Helge Bischoff, Marc A. Schneider, Petros Christopoulos, Uwe Haberkorn, Claus Peter Heussel, Inka Zoernig, Felix J. F. Herth, Michael Thomas, Alexander Rölle, Hauke Winter, Axel Benner, Dirk Jaeger, Martin E. Eichhorn   +19 more
wiley   +1 more source

A Feasibility Study of [¹⁸F]F-AraG Positron Emission Tomography (PET) for Cardiac Imaging-Myocardial Viability in Ischemia-Reperfusion Injury Model. [PDF]

Mol Imaging Biol
Shrestha UM, Chae HD, Fang Q, Lee RJ, Packiasamy J, Huynh L, Blecha J, Huynh TL, VanBrocklin HF, Levi J, Seo Y.   +10 more
europepmc   +1 more source

Clinical and Radiometabolic Correlatives of ddPCR Liquid Biopsy for BRAF V600 Mutated Melanoma

International Journal of Cancer, EarlyView.
Commercial circulating tumor DNA (ctDNA) liquid biopsy tests are increasingly used for disease monitoring and surveillance in melanoma. However, data regarding the possible correlations between ctDNA and baseline clinical and radiometabolic parameters such as metastatic locations, tumor volume, and tumor glycolysis in patients with BRAF‐mutated ...
Ronen Stoff, Gokce Belge Bilgin, Yalda Nikanpour, Geoffrey B. Johnson, Benjamin R. Kipp, David M. Zahrieh, Katherine B. Geiersbach, Matthew S. Block, Svetomir N. Markovic   +8 more
wiley   +1 more source

Deep learning generation of preclinical positron emission tomography (PET) images from low-count PET with task-based performance assessment. [PDF]

Med Phys
Dutta K, Laforest R, Luo J, Jha AK, Shoghi KI.   +4 more
europepmc   +1 more source

The 9th Edition of the UICC TNM Classification of Malignant Tumours: Updates and Rationale for Change

International Journal of Cancer, EarlyView.
ABSTRACT The standard for assessing and recording the extent of the tumour, a necessity for most malignancies, is the Tumour Node Metastases (TNM) classification. The Union for International Cancer Control (UICC) TNM committee has defined this since the early 1950s.
James D. Brierley, Liesbet J. Van Eycken, Meredith E. Giuliani, Brian A. Rous, Shao Hui Huang, Hisao Asamura, Mary K. Gospodarowicz, Anne W. Lee, Brian O'Sullivan   +8 more
wiley   +1 more source

Current Role and Future Prospects of Positron Emission Tomography (PET)/Computed Tomography (CT) in the Management of Breast Cancer. [PDF]

Medicina (Kaunas)
Robson N, Thekkinkattil DK.
europepmc   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, EarlyView.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source